

# **INTRODUCTION**



Univ.-Prof. Dr. Richard Greil President AGMT

Dear colleagues,

the peripheral blood.

it is my great pleasure to welcome you to the 2nd Salzburg Gastrointestinal Cancer Summit of the AGMT and the Salzburg Cancer Research Institute in cooperation with the Cancer Cluster Salzburg. This year's event will focus on colorectal cancer, which is one of the most common cancers worldwide with more than 1 million new cases per year. Following the recent description of consensus molecular subtypes of colorectal cancer, it is important to assess their clinical relevance and to design new concepts of subtype-adapted therapy. Friday evening will be devoted to this topic, with lectures on basic

research, clinical aspects and new methodical approaches to the molecular analysis in

In colorectal cancer the interdisciplinary discussion of individual patients is of utmost importance: thereby more and more patients can be treated with curative intent despite metastatic disease. In addition to the clinical discussion, it is also important to advance scientific progress and thus jointly expand the limits of our possibilities. In this year's programme, numerous experts in the field of surgery as well as radiotherapy will share their views on colorectal cancer.

Despite the undoubted importance of immunotherapy in microsatellite-instable colorectal cancer, a plethora of questions are arising regarding its potential use in the much more frequent microsatellite-stable variant. Our programme is also dedicated to elucidate some of these questions.

We will put all our efforts in providing a lively and exciting platform for a critical exchange between clinicians and scientists across all disciplines. With this in mind, I wish you an interesting discussion and a pleasant stay in Salzburg and would like to thank you for attendance.

# **PROGRAM**

#### Friday, November 23, 2018

17:00-17:15 Welcome and introduction

Prof. Dr. Richard Greil, Salzburg

17:15–19:15 Session 1: Molecular Biology of Colorectal Cancer

Chair: Prof. Dr. Richard Greil, Salzburg

Molecular Consensus Subtypes – Translational Science

Molecular Consensus Subtypes - Clinical Implications

Circulating Tumor DNA in Colorectal Cancer

Lirculating Tumor DNA in Color

Prof. Dr. Sabine Tejpar, Leuven
Prof. Dr. Sebastian Stintzing, Munich
Prof. Dr. Armin Gerger, Graz

15:30 - 15:45

\* Discussion after lecture

15:45

Farewell with regional delicacies



# Saturday, November 24, 2018

09:15 - 10:30	Session 2: Rectal Cancer Chair: Prof. Dr. Dieter Öfner-Velano, Innsbruck	
	No Surgery? Watch & Wait Strategy for Clinically Complete Remission after Neoadjuvant Chemoradiotherapy*	Prof. Dr. Felix Sedlmayer, Salzburg
	Current Data & New Concepts for Postoperative Systemic Therapy*	Prof. Dr. Richard Greil, Salzburg
	New Trends in Surgery of Rectal Cancer*	PD Dr. Adam Dinnewitzer, Salzburg
10:30 - 10:45	Coffee break	
10:45 - 12:00	Session 3: Surgery in Metastatic Disease Chair: Prof. Dr. Klaus Emmanuel, Salzburg, PD Dr. Felix Aigner, Berlin	
	Limits of Resectability of Liver-Metastases: Eminence or Evidence?	Prof. Dr. Hubert Stein, Nürnberg
	Peritonectomy & Intraperitoneal Therapy	Dr. Tarkan Jäger, Salzburg
	Panel discussion: The Future of Surgery in Metastatic CRC Chair: Prof. Dr. Richard Greil, Salzburg Panelists: Prof. Emmanuel, PD Aigner, Prof. Stein, Prof. Öfner-Veland	0
12:00 – 12:45	Lunch buffet	
12:45 - 14:00	Session 4: Immunology & Sidedness Chair: Prof. Dr. Richard Greil, Salzburg	
	Tumor Immunology in CRC*	Prof. Dr. Zlatko Trajanoski, Innsbruck
	Immune Checkpoint Blockade in CRC*	PD Dr. Lukas Weiss, Salzburg
	Primary Tumor Localisation in mCRC: Open Questions?*	Prof. Dr. Wolfgang Eisterer, Klagenfun
14:00 - 14:15	Coffee break	
14:15 - 15:30	Session 5: Open Questions of 3rd Line Therapy & Outlook into New Therapeutic Concepts Chair: Prof. Dr. Wolfgang Eisterer, Klagenfurt	
	3L Therapy: PRO Sequence Regorafenib > TAS-102	Dr. Florian Huemer, Salzburg
	3L Therapy: PRO Sequence TAS-102 > Regorafenib	Prof. Dr. Gerald Prager, Vienna
	Discussion: Therapy Sequence from the 3rd Line	
	Bispecific Targeting of Tumors*	Dr. Christian Klein, Roche Innovation Center, Zurich
	Tumor Treating Fields in the Treatment of Solid Tumors*	PD Dr. Lukas Weiss, Salzburg

Prof. Dr. Richard Greil, Salzburg



### **Sheraton Grand Salzburg**

Auerspergstrasse 4, 5020 Salzburg Telefon +43 662 88 999 0 E-Mail: sheraton.salzburg@sheraton.com

# **Crediting of the event:**

DFP approved event (10 points)

### **Organisation:**

Prof. Dr. Richard Greil PD Dr. Lukas Weiss

AGMT gemeinnützige GmbH | www.agmt.at

Salzburg Cancer Research Institute (SCRI) with

Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)

www.limcr.at and

Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)

www.cccit.at

in cooperation with the

Cancer Cluster Salzburg | www.cancercluster-salzburg.at and acoasso | www.aco-asso.at



**ARBEITSGEMEINSCHAFT MEDIKAMENTÖSE TUMORTHERAPIE** 



Österreichische Gesellschaft für Chirurgische Onkologie Austrian Society of Surgical Oncology



Center for Clinical Cancer and Immunology Trials

LIMCR Laboratory for Immunological and Molecular Cancer Research



This map was created with data from OpenStreetMap (www.openstreetmap.org). The map can be

used and modified under the Open Data Commons Open Database Licence (ODbL).

Kindly supported by:













